[Translated article] Generational priorities, motivations, concerns, and expectations of hospital pharmacists in Spain [0.03%]
西班牙不同代际药剂师的优先事项、动机、关注点和期待
Covadonga Pérez Menéndez Conde,Beatriz Martínez Castro,María Pérez Abánades et al.
Covadonga Pérez Menéndez Conde et al.
Objective: To analyze generational differences in priorities, motivations, concerns, and professional expectations among pharmacists working in Hospital Pharmacy Services in Spain, in order to generate actionable evidence...
[Translated article] Safety of Bruton kinase inhibitors in chronic lymphocytic leukemia: Real world clinical practice [0.03%]
布鲁顿激酶抑制剂在慢性淋巴细胞白血病中的安全性：临床实践中的真实世界数据
Rocío Bello-Calvo,Rita González-Resina,Araceli Rubio-Martínez et al.
Rocío Bello-Calvo et al.
Introduction: Bruton's tyrosine kinase inhibitors (BTKi) have replaced immunochemotherapy in patients with chronic lymphocytic leukemia (CLL). The safety profile, particularly in monotherapy indications under real-world c...
Standardized classification of pharmaceutical interventions in intensive care units [0.03%]
重症监护病房药物干预的标准化分类法
Esther Domingo Chiva,Fernando Becerril Moreno,Miguel Ángel Amor García et al.
Esther Domingo Chiva et al.
A standardized classification system was developed to harmonize the documentation of pharmaceutical interventions throughout the pharmacotherapeutic process in intensive care units caring for critically ill adult patients. The Intensive Car...
[Translated article] Gender perspective in medication-related problems resulting in emergency department attendance involving high-alert medications [0.03%]
高警戒药物引发用药问题而急诊就诊的性别差异分析
Concepción Marín de la Bárcena,Jesús Ruiz Ramos,Mireia Puig Campmany et al.
Concepción Marín de la Bárcena et al.
Objectives: To characterize medication-related problems resulting in emergency department attendance involving high-alert medications, paying particular attention to sex-related differences in the type of the problem and ...
Isabel Romero Crespo,Maria Luisa Gaspar Carreño,Maria Cristina Muñoz Contreras
Isabel Romero Crespo
Objective: To review the most relevant aspects to consider when selecting the optimal surface disinfectant for use in healthcare settings. Method: ...
Real-world evidence of immune-related adverse events as predictive factor of response in non-small cell lung cancer [0.03%]
真实世界证据：免疫相关不良事件可作为非小细胞肺癌应答的预测因素
Maria Susana Fortes-Gonzalez,Silvia Vazquez-Blanco,Leticia Herrero-Poch et al.
Maria Susana Fortes-Gonzalez et al.
Objective: The aim of the study was to assess whether immune-related adverse events (irAE) act as predictive biomarkers of response to immune checkpoint inhibitors in non-small-cell lung cancer in real-life practice. ...
[Translated article] Spanish consensus on the preparation of parenteral nutrient mixtures - General aspects [0.03%]
西班牙制备肠外营养混合物的共识声明-总则方面
David Berlana,Pilar Gomis Muñoz,Natividad Lago et al.
David Berlana et al.
Parenteral nutrition is a complex therapeutic intervention, particularly in pediatric and critically ill patients, requiring strict standards of safety, stability, and compatibility during its preparation. To update and harmonize clinical p...
Pharmacologic and pharmacokinetic factors in blood donation: A risk-based deferral framework proposal [0.03%]
药物和药代动力学因素在血液捐赠中的作用：基于风险的延期框架建议
Roberto Lozano,María-Esther Franco,Carina Bona
Roberto Lozano
Objective: The presence of residual medications in blood donors can pose a risk to transfusion recipients, especially when drugs remain in plasma at clinically relevant levels. Current deferral recommendations for medicat...
Possible severe gastrointestinal toxicity following the first cycle of mirvetuximab soravtansine in a patient with high-grade serous ovarian carcinoma [0.03%]
接受mirvetuximab soravtansine治疗的高级别浆液性卵巢癌患者的首个周期后可能出现严重胃肠道毒性反应
Carlota Rodríguez-Tenreiro Rodríguez,Alicia Caso González,Marina Muñoz Villasur et al.
Carlota Rodríguez-Tenreiro Rodríguez et al.
Real world outcomes of first-line pembrolizumab in metastatic non-small-cell lung cancer [0.03%]
帕博利珠单抗一线治疗晚期非小细胞肺癌的现实世界结局研究
Amparo Burgos,Teresa Calleja,María Sacramento Díaz et al.
Amparo Burgos et al.
Objective: To describe the effectiveness and safety of pembrolizumab in routine clinical practice as first-line treatment for advanced/metastatic non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50% and without ...